Volume 2, Issue 1, June 2018, Page: 20-24
Prevalence of Epstein–Barr Virus in Patients with Ulcerative Colitis Using Polymerase Chain Reaction (PCR)
Maryam Derakhshan, Department of Pathology, Al-Zahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
Pegah Hedayat, Department of Pathology, Al-Zahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
Rozhan Mohammadi, Department of Pathology, Al-Zahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
Amirsajad Barahimi, Department of General Physician, Al-Zahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
Received: Jun. 22, 2018;       Accepted: Aug. 3, 2018;       Published: Sep. 10, 2018
DOI: 10.11648/j.plm.20180201.14      View  296      Downloads  16
Abstract
Ulcerative colitis (UC) is still controversial and recent researches referred to the role of infectious factors such as EBV in this disease, but the relationship between EBV and UC has not yet been proven. Therefore, the present study evaluates the prevalence of EBV in patients with UC and comparison with control group by Polymerase Chain Reaction (PCR). In this study, 30 samples of intestinal biopsy in patients with UC in the active phase of disease and 30 biopsy samples from non-UC subjects were evaluated by PCR method were evaluated by PCR method and the presence or absence of EBV virus in the sample was recorded. Finally, the collected data were analyzed by SPSS (Ver.22) software. As the result EBV was found in 10 biopsies of 30 from UC patients and 3 of 30 biopsies from non-UC-patients (33.3% vs. 10%, P-value = 0.028). Also, the prevalence of this virus in the both groups was not significantly different in terms of sex and age (P-value > 0.05). Therefore, it may conclude that evidence of infection of the virus in mucosal inflammatory cells of patients with UC has an important role in chronic UC. Given the small sample size, it is suggested that future studies to be carried out with similar subject in a larger population of these patients.
Keywords
Epstein–Barr Virus, Ulcerative Colitis, Polymerase Chain Reaction
To cite this article
Maryam Derakhshan, Pegah Hedayat, Rozhan Mohammadi, Amirsajad Barahimi, Prevalence of Epstein–Barr Virus in Patients with Ulcerative Colitis Using Polymerase Chain Reaction (PCR), Pathology and Laboratory Medicine. Vol. 2, No. 1, 2018, pp. 20-24. doi: 10.11648/j.plm.20180201.14
Copyright
Copyright © 2018 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn’s disease. Lancet 2017; 389:1741-1755.
[2]
Aghazadeh R, Zali MR, Bahari A, Amin K, Ghahghaie F, Firouzi F. Inflammatory bowel disease in Iran: a review of 457 cases. J GastroenterolHepatol 2005; 20(11): 1691-5.
[3]
Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet 2017; 389:1756-1770.
[4]
Mokhtari M, Hashemi JM, Davarpanah JA. Prevalence of Anti-EBV Antibodies in Adult Patients with Nasopharyngeal Carcinoma During 2003-2007 In Isfahan, Iran. Iranian Journal of Cancer Prevention, 2009; 1(4): 173-177.
[5]
Haahr S, H?llsberg P. Multiple sclerosis is linked to Epstein-Barr virus infection. Rev Med Virol 2006; 16(5): 297-310.
[6]
Green C, Elliott L, Beaudoin C, Bernstein CN. A. population-based ecologic study of inflammatory bowel disease: searching for etiologic clues. Am J Epidemiol 2006; 164(7): 615-23.
[7]
Linton MS, Kroeker K, Fedorak D, Dieleman L, Fedorak RN. Prevalence of Epstein–Barr Virus in a population of patients with inflammatory bowel disease: a prospective cohort study. Alimentary pharmacology & therapeutics. 2013 Nov 1; 38(10):1248-54.
[8]
Mokhtari M, Bahraini M, Masoudifar A. EPSTEIN-BARR VIRUS NUCLEAR ANTIGEN EXPRESSION (EBNA) IN PAPILLARY THYROID CARCINOMA. Journal of Fundamental and Applied Sciences. 2016 Feb 15; 8(2S):2360-5.
[9]
Magro F, Santos-Antunes J, Albuquerque A, Vilas-Boas F, Macedo GN, Nazareth N, Lopes S, Sobrinho-Simões J, Teixeira S, Dias CC, Cabral J. Epstein–Barr Virus in Inflammatory Bowel Disease—Correlation with Different Therapeutic Regimens. Inflammatory bowel diseases. 2013 Jul 1; 19(8):1710-6.
[10]
Cohen JI: Epstein-Barr virus infection. N Engl J Med 2000; 343:481–492.
[11]
Liebowitz D. Pathogenesis of Epstein-Barr virus. In: McCance DJ, Editor. Human tumor viruses. Washington, DC: American Society for Microbiology; 1998. p. 175-9.
[12]
Luzuriaga K, Sullivan JL: Infectious mononucleosis. N Engl J Med 2010; 362:1993–2000.
[13]
Yanai H, Shimizu N, Nagasaki S, Mitani N, Okita K. Epstein-Barr virus infection of the colon with inflammatory bowel disease. Am J Gastroenterol 1999; 94(6): 1582-6.
[14]
Gehlert T, Devergne O, Niedobitek G. Epstein-Barr virus (EBV) infection and expression of the interleukin-12 family member EBV-induced gene 3 (EBI3) in chronic inflammatory bowel disease. J Med Virol 2004; 73(3): 432-8.
[15]
Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55:749.
[16]
Spieker T, Herbst H. Distribution and phenotype of Epstein-Barr virus-infected cells in inflammatory bowel disease. Am J Pathol 2000; 157(1): 51-7.
[17]
Wakefield AJ, Fox JD, Sawyerr MA, Taylor JE, Sweenie CH, Smith M, et al. Detection of herpesvirus DNA in the large intestine of patients with ulcerative colitis and Crohn's disease using the nested polymerase chain reaction. Journal of Medical Virology 1992; 38(3): 183-90.
[18]
Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study, N Engl J Med, 1987; 317: 1625-29.
[19]
Dimitroulia E, Pitiriga VC, Piperaki ET, Spanakis NE, Tsakris A. Inflammatory bowel disease exacerbation associated with Epstein-Barr virus infection. Dis Colon Rectum 2013; 56(3): 322-7.
[20]
Takeda Y, Takada K, Togashi H, Takeda H, Sakano M, Osada Y, et al. Demonstration of Epstein-Barr virus localized in the colonic and ileal mucosa of a patient with ulcerative colitis. GastrointestEndosc 2000; 51(2): 205-9.
[21]
Ameli M, Khalily F. Analysis ulcerative colitis for presence Epstein-Barr virus DNA sequences by polymerase chain reaction technique. Journal of Analytical Research in Clinical Medicine. 2016 Jan 1; 4(1):9-13.
[22]
Matsumoto H, Kimura Y, Murao T, Osawa M, Akiyama T, Mannoji K, Koresawa R, Tokunaga H, Wada H, Sugihara T, Haruma K. Severe colitis associated with both epstein-barr virus and cytomegalovirus reactivation in a patient with severe aplastic anemia. Case reports in gastroenterology. 2014; 8(2):240-4.
[23]
Mehrabani-Khasraghi S, Ameli M, Khalily F. Analysis ulcerative colitis for presence Epstein-Barr virus DNA sequences by polymerase chain reaction technique. J Anal Res Clin Med, 2016; 4(1): 9-13.
[24]
Ryan JL, Shen YJ, Morgan DR, Thorne LB, Kenney SC, Dominguez RL, Gulley ML: Epstein-Barr virus infection is common in inflamed gastrointestinal mucosa. Dig Dis Sci 2012; 57:1887–1898.
[25]
Rizzo AG, Orlando A, Gallo E, Bisanti A, Sferrazza S, Montalbano LM, Macaluso FS, Cottone M. Is Epstein-Barr virus infection associated with the pathogenesis of microscopic colitis?. Journal of Clinical Virology. 2017; 97:1-3.
Browse journals by subject